Status and future direction of male contraceptive development
| Autor: | Lyttle Cr, Kopf Gs |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Pharmacology Gynecology Economic growth medicine.medical_specialty Product innovation business.industry media_common.quotation_subject Contraceptive Agents Male Societal impact of nanotechnology Fertility Private sector Spermatogenesis-Blocking Agents Family planning Drug Discovery Overpopulation Global health medicine Humans business Unintended pregnancy media_common |
| Zdroj: | Current Opinion in Pharmacology. 3:667-671 |
| ISSN: | 1471-4892 |
| DOI: | 10.1016/j.coph.2003.07.002 |
| Popis: | Control of fertility constitutes a global health issue, as overpopulation and unintended pregnancy have both major personal and societal impact. Although the contraceptive revolution in the 1960s following the development of hormonal-based oral contraceptives for women has had a major impact on societal dynamics in several cultures, little product innovation has occurred since then. One solution to this global health issue lies in the development of new and innovative contraceptives for both women and men, the goal of which is to provide a range of options for people at all stages and walks of life. Currently, three options for male-based contraception exist (i.e. withdrawal, condoms and vasectomy), and these are acknowledged as woefully inadequate. Introduction of new forms of male contraception based on both hormonal and non-hormonal paradigms are wanted and needed; this need is now becoming recognized by both the public and private sectors. New and innovative products will come from our knowledge of the unique physiology and genetics of reproduction, as well as by exploiting existing and future genomics, proteomics and protein network platforms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect